A randomised phase III clinical trial investigating the effect of Fragmin® added to standard therapy In patients with lung cancer

Phase 3

Completed

• Conditions: ung cancer; Cancer; Malignant neoplasm of bronchus and lung

• Registration Number: ISRCTN80812769
• Lead Sponsor: Velindre NHS Trust (UK)

Brief Summary

2009 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/19807917 protocol 2016 Results article in http://www.ncbi.nlm.nih.gov/pubmed/26700124 results 2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/27439472 results

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-07-08
• Study Completion: 2011-10-31
• Last Update Posted: 7 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 2202

Inclusion Criteria

Patients with histopathologically or cytologically confirmed primary lung cancer of any stage or histology.

Exclusion Criteria

1. Patients with other intrathoracic tumours (e.g. carcinoid, mesothelioma, lymphoma, lung metastases from another primary site)
2. Any previous illness or treatment likely to interfere with protocol treatment or comparisons
3. Known cerebral metastases
4. Haemoptysis of CTC Grade two (symptomatic haemoptysis requiring medical intervention) or above
5. Known bleeding diathesis
6. Known pregnancy or lactation
7. Known allergy to heparin
8. Platelet count lower than 100 x 10^9/l
9. Renal impairment with serum creatinine greater than 150 µmol/l
10. Patients who have received therapeutic anticoagulation in the last 12 months
11. Patients taking Ketorolac

Study & Design

• Study Type: Interventional
• Study Design: Not specified